AstraZeneca has presented new evidence from its TULIP Phase III program showing that SAPHNELO (anifrolumab-fnia), a first-in-class biologic for patients with systemic lupus erythematosus (SLE), is more likely to achieve and sustain remission compared to standard therapy alone. The data will be presented at the annual meeting of the American College of Rheumatology (ACR). The company also highlighted positive results from the FASENRA (benralizumab) MANDARA Phase III trial, the first head-to-head trial of biologics to treat eosinophilic granulomatosis with polyangiitis (EGPA).